MedPath

Efficacy of Vitamin C Supplementation on Malondialdehid Levels and Disease Activity in SLE Patients

Not Applicable
Completed
Conditions
Systemic Lupus Erythematosus (SLE)
Registration Number
NCT07083622
Lead Sponsor
Universitas Sriwijaya
Brief Summary

The study aimed to evaluate the efficacy of vitamin C supplementation compared to placebo towards malondialdehid levels and disease activity with the MEX-SLEDAI score in Systemic Lupus Erythematosus (SLE) patients. The current study was designed as a single-center double-blind randomized controlled clinical trial. The participants were voluntarily recruited ≥ 18 years old SLE patients, with mild to moderate disease activity and did not consumed vitamin C 1 week prior to the trial study. Participants were randomized into two groups receiving vitamin C supplementation, or placebo. Malondialdehid levels and MEX-SLEDAI score were evaluated at the beginning and at the end of the 8 week trial for analysis.

Detailed Description

This research is a double blind randomized controlled trial study. The study subjects were 38 patients diagnosed with mild to moderate lupus activity, randomly divided into 2 groups, who received vitamin C supplementation twice daily for 8 weeks and the group that received placebo. Serum malondialdehid levels and the degree of disease activity using MEX-SLEDAI score were measured before and after treatment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
38
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
MEX-SLEDAIFrom enrollment to the end of the treatment at 8 weeks

To determine the effectiveness of adding vitamin C compared to placebo towards disease activity in SLE patients, measured with MEX-SLEDAI score

MalondialdehidFrom enrollment to the end of the treatment at 8 weeks

To determine the effectiveness of adding vitamin C compared to placebo towards malondialdehid levels concentration change in SLE patients.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Mohammad Hoesin General Hospital

🇮🇩

Palembang, South Sumatera, Indonesia

Mohammad Hoesin General Hospital
🇮🇩Palembang, South Sumatera, Indonesia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.